We are live on ! Find out more
ANVS icon

Annovis Bio
ANVS

42 hedge funds and large institutions have $4.19M invested in Annovis Bio in 2025 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 8 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

87% more call options, than puts

Call options by funds: $419K | Put options by funds: $224K

25% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 8

7% more capital invested

Capital invested by funds: $3.93M → $4.19M (+$260K)

1.09% more ownership

Funds ownership: 9.3% → 10.39% (+1.1%)

0% more funds holding

Funds holding: 42 → 42 (0)

0% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 5

Holders
42
Holders Change
–
Holders Change %
0%
% of All Funds
0.55%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
10
Reduced
8
Closed
5
Calls
$419K
Puts
$224K
Net Calls
+$195K
Net Calls Change
+$149K

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$362K
2
Northern Trust
Northern Trust
Illinois
+$154K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$135K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$103K
5
XT
XTX Topco
Cayman Islands
+$72.1K

Top Sellers

Rank Fund Capital Flow
1
Marshall Wace
Marshall Wace
United Kingdom
-$197K
2
UBS Group
UBS Group
Switzerland
-$64.2K
3
Jane Street
Jane Street
New York
-$51.6K
4
MFG
Merit Financial Group
Georgia
-$25K
5
CAMG
CWA Asset Management Group
Florida
-$15K
Name Holding Trade Value Shares
Change 		Change in
Stake
Simplex Trading
26
Simplex Trading
Illinois
$8K -$35 -14 -0.3%
C
27
Covestor
United Kingdom
$5K – – –
FIA
28
FNY Investment Advisers
New York
$4K +$5K +2,000 New
SS
29
SBI Securities
Japan
$2.96K -$80 -32 -2%
DPW
30
DiNuzzo Private Wealth
Pennsylvania
$2.31K – – –
TRCT
31
Tower Research Capital (TRC)
New York
$2.11K +$2.55K +1,021 New
SPIA
32
Steward Partners Investment Advisory
New York
$2.07K – – –
Rockefeller Capital Management
33
Rockefeller Capital Management
New York
$2.07K +$2.5K +1,000 New
UBS Group
34
UBS Group
Switzerland
$1.31K -$64.2K -25,684 -98%
BF
35
BOK Financial
Oklahoma
$1.15K – – –
PNC Financial Services Group
36
PNC Financial Services Group
Pennsylvania
$745 – – –
RhumbLine Advisers
37
RhumbLine Advisers
Massachusetts
$724 – – –
RA
38
Rise Advisors
New York
$689 – – –
LFG
39
Larson Financial Group
Missouri
$621 – – –
IA
40
IFP Advisors
Florida
$435 +$250 +100 +91%
Osaic Holdings
41
Osaic Holdings
Arizona
$429 -$1.17K -467 -69%
Bank of America
42
Bank of America
North Carolina
$300 -$25 -10 -6%
Marshall Wace
43
Marshall Wace
United Kingdom
– -$197K -90,907 Closed
Jane Street
44
Jane Street
New York
– -$51.6K -23,798 Closed
Royal Bank of Canada
45
Royal Bank of Canada
Ontario, Canada
– -$3K -1,564 Closed
Raymond James Financial
46
Raymond James Financial
Florida
– -$1.18K -544 Closed
CIAM
47
Caitong International Asset Management
Hong Kong
– -$2 -1 Closed
1
2

ANVS Hedge Fund Activity: Q3 2025 in Review

42 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Annovis Bio (ANVS) for Q3 2025, worth a combined $4.19M — up 6.6% from $3.93M a quarter earlier.

Fund positioning in ANVS was balanced in Q3 2025: 5 funds opened new positions, 5 closed out, 10 added to existing stakes and 8 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $362K. The largest seller was Marshall Wace, exiting entirely with an estimated $197K sold.

  • 42 institutional investors held Annovis Bio (ANVS) as of Q3 2025, unchanged from Q2 2025.
  • Funds reported $4.19M of Annovis Bio stock for Q3 2025, up 6.6% quarter-over-quarter.
  • 5 funds opened new Annovis Bio positions in Q3 2025 and 5 closed out, a net change of 0 holders.
  • The largest Annovis Bio buyer in Q3 2025 was Citadel Advisors, an estimated $362K added.
  • The largest Annovis Bio seller in Q3 2025 was Marshall Wace, an estimated $197K sold.

Based on aggregated 13F filings for Q3 2025.